ABOUT US
“Bridging science and communication is essential to transforming discoveries into real-world solutions for patients with diabetes.”
Joana RN Lemos, MSc, PhD
Associate Director of Scientific Communications and Data Analytics; Research Assistant Professor, Department of Medicine, Division of Endocrinology, Diabetes, and Metabolism, Diabetes Research Institute,
University of Miami, Miller School of Medicine
DRI Affinity Groups: Immunology, Device Transplant, and Beta cell robustness and augmentation, function enhancement and islet cross talk
Read more
An international leader in scientific communications, Dr Joana RN Lemos focuses on bridging research innovation with stakeholder engagement. A seasoned clinical researcher and biostatistician, Dr Lemos has extensive expertise in diabetes research, islet transplantation, and immunotherapy. She leads multiple initiatives to foster collaboration between researchers, clinicians, and industry partners, aiming to advance therapies for patients with diabetes.
Dr Lemos is deeply committed to advancing the prevention and cure of T1D, a cause that is especially meaningful to her as several of her family members and friends are affected by the disease. Outside of work, Dr Lemos enjoys being close to the ocean, sailing, and exploring art and music. Her passion for science is matched by her appreciation for creativity and nature.
Dr Lemos specializes in islet transplantation, immunotherapy, and beta cell replacement strategies for T1D. Her work emphasizes clinical trial design, data integrity, and advanced statistical methodologies to optimize research outcomes. She also focuses on innovative communication strategies to effectively translate scientific discoveries for diverse audiences. By integrating data analytics with strategic communications, Dr Lemos aims to enhance collaboration and accelerate the development of novel therapies for diabetes.
To develop and implement strategic communication initiatives that effectively translate complex scientific discoveries into accessible information for donors, stakeholders, and the broader public, thereby enhancing support for T1D research and accelerating the path to prevention and cure.